Cargando…

Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation

Skeletal uptake of radiolabeled‐1, 4, 7, 10‐tetraazacyclododecane‐1, 4, 7, 10‐tetramethylene phosphoric acid (e.g., (177)Lu‐DOTMP) complex, is used for bone pain palliation. The moderate energy of β‐emitting [Formula: see text] has been considered as a potential radionuclide for development of the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Salek, Nafise, Shamsaei, Mojtaba, Maragheh, Mohammad Ghannadi, Arani, Simindokht Shirvani, Samani, Ali Bahrami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690526/
https://www.ncbi.nlm.nih.gov/pubmed/27929488
http://dx.doi.org/10.1120/jacmp.v17i6.6375
_version_ 1783279627112808448
author Salek, Nafise
Shamsaei, Mojtaba
Maragheh, Mohammad Ghannadi
Arani, Simindokht Shirvani
Samani, Ali Bahrami
author_facet Salek, Nafise
Shamsaei, Mojtaba
Maragheh, Mohammad Ghannadi
Arani, Simindokht Shirvani
Samani, Ali Bahrami
author_sort Salek, Nafise
collection PubMed
description Skeletal uptake of radiolabeled‐1, 4, 7, 10‐tetraazacyclododecane‐1, 4, 7, 10‐tetramethylene phosphoric acid (e.g., (177)Lu‐DOTMP) complex, is used for bone pain palliation. The moderate energy of β‐emitting [Formula: see text] has been considered as a potential radionuclide for development of the bone‐seeking radiopharmaceutical. Since the specific activity of the radiolabeled carrier molecules should be high, the “no‐carrier‐added radionuclides” have significant roles in nuclear medicine. Many researchers illustrated no‐carrier‐added (177)Lu production; among these separation techniques such as ion exchange chromatography, reversed phase ion‐pair, and electrochemical method, extraction chromatography has been considered more capable than other methods. In order to optimize the conditions, some effective factors on separation of Lu/Yb were investigated by EXC. The NCA (177)Lu, produced by this method, was mixed with [Formula: see text] of DOTMP solution (20 mg in 1 mL of 0.5 M NaHCO(3), [Formula: see text]) and incubated under stirring at room temperature for 45 min. Radiochemical purity of the (177)Lu‐DOTMP complex was determined using radio‐thin‐layer chromatography (RTLC) method. The complex was injected to wild‐type rats and biodistribution was then studied for seven days. The NCA (177)Lu was produced with specific activity of 48 Ci/mg and with a radinuclidic purity of 99.99% through irradiation of enriched (176)Yb target (1 mg) in a thermal neutron flux of [Formula: see text] for 14 days. (177)Lu‐DOTMP was obtained with high radiochemical purities ([Formula: see text]) under optimized reaction conditions. The radiolabeled complex exhibited excellent stability at room temperature. Biodistribution of the radiolabeled complex studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation within the other nontargeted organs. PACS number(s): 87.57.un, 87.57.uq
format Online
Article
Text
id pubmed-5690526
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56905262018-04-02 Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation Salek, Nafise Shamsaei, Mojtaba Maragheh, Mohammad Ghannadi Arani, Simindokht Shirvani Samani, Ali Bahrami J Appl Clin Med Phys Radiation Oncology Physics Skeletal uptake of radiolabeled‐1, 4, 7, 10‐tetraazacyclododecane‐1, 4, 7, 10‐tetramethylene phosphoric acid (e.g., (177)Lu‐DOTMP) complex, is used for bone pain palliation. The moderate energy of β‐emitting [Formula: see text] has been considered as a potential radionuclide for development of the bone‐seeking radiopharmaceutical. Since the specific activity of the radiolabeled carrier molecules should be high, the “no‐carrier‐added radionuclides” have significant roles in nuclear medicine. Many researchers illustrated no‐carrier‐added (177)Lu production; among these separation techniques such as ion exchange chromatography, reversed phase ion‐pair, and electrochemical method, extraction chromatography has been considered more capable than other methods. In order to optimize the conditions, some effective factors on separation of Lu/Yb were investigated by EXC. The NCA (177)Lu, produced by this method, was mixed with [Formula: see text] of DOTMP solution (20 mg in 1 mL of 0.5 M NaHCO(3), [Formula: see text]) and incubated under stirring at room temperature for 45 min. Radiochemical purity of the (177)Lu‐DOTMP complex was determined using radio‐thin‐layer chromatography (RTLC) method. The complex was injected to wild‐type rats and biodistribution was then studied for seven days. The NCA (177)Lu was produced with specific activity of 48 Ci/mg and with a radinuclidic purity of 99.99% through irradiation of enriched (176)Yb target (1 mg) in a thermal neutron flux of [Formula: see text] for 14 days. (177)Lu‐DOTMP was obtained with high radiochemical purities ([Formula: see text]) under optimized reaction conditions. The radiolabeled complex exhibited excellent stability at room temperature. Biodistribution of the radiolabeled complex studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation within the other nontargeted organs. PACS number(s): 87.57.un, 87.57.uq John Wiley and Sons Inc. 2016-11-08 /pmc/articles/PMC5690526/ /pubmed/27929488 http://dx.doi.org/10.1120/jacmp.v17i6.6375 Text en © 2016 The Authors. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Salek, Nafise
Shamsaei, Mojtaba
Maragheh, Mohammad Ghannadi
Arani, Simindokht Shirvani
Samani, Ali Bahrami
Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
title Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
title_full Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
title_fullStr Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
title_full_unstemmed Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
title_short Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
title_sort production and quality control (177)lu (nca)—dotmp as a potential agent for bone pain palliation
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690526/
https://www.ncbi.nlm.nih.gov/pubmed/27929488
http://dx.doi.org/10.1120/jacmp.v17i6.6375
work_keys_str_mv AT saleknafise productionandqualitycontrol177luncadotmpasapotentialagentforbonepainpalliation
AT shamsaeimojtaba productionandqualitycontrol177luncadotmpasapotentialagentforbonepainpalliation
AT maraghehmohammadghannadi productionandqualitycontrol177luncadotmpasapotentialagentforbonepainpalliation
AT aranisimindokhtshirvani productionandqualitycontrol177luncadotmpasapotentialagentforbonepainpalliation
AT samanialibahrami productionandqualitycontrol177luncadotmpasapotentialagentforbonepainpalliation